Daniel Brennan - Boston Scientific Ex CFO
| BSX Stock | EUR 85.50 1.50 1.72% |
Insider
Daniel Brennan is Ex CFO of Boston Scientific
| Age | 57 |
| Phone | 508 683 4000 |
| Web | https://www.bostonscientific.com |
Daniel Brennan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Brennan against Boston Scientific stock is an integral part of due diligence when investing in Boston Scientific. Daniel Brennan insider activity provides valuable insight into whether Boston Scientific is net buyers or sellers over its current business cycle. Note, Boston Scientific insiders must abide by specific rules, including filing SEC forms every time they buy or sell Boston Scientific'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Brennan over six months ago Disposition of 1644 shares by Daniel Brennan of Boston Scientific at 65.82 subject to Rule 16b-3 |
Boston Scientific Management Efficiency
The company has return on total asset (ROA) of 0.0393 % which means that it generated a profit of $0.0393 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0408 %, meaning that it generated $0.0408 on every $100 dollars invested by stockholders. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ivan Fong | Medtronic PLC | 62 | |
| Melissa Brotz | Abbott Laboratories | N/A | |
| Arnold Pinkston | Edwards Lifesciences | 64 | |
| Donald Bobo | Edwards Lifesciences | 61 | |
| Daniel Salvadori | Abbott Laboratories | 44 | |
| Dirksen Lehman | Edwards Lifesciences | N/A | |
| Michelle Quinn | Becton Dickinson and | N/A | |
| Hubert Allen | Abbott Laboratories | 57 | |
| Scott Ullem | Edwards Lifesciences | 56 | |
| Robert Funck | Abbott Laboratories | 62 | |
| Spencer Stiles | Stryker | 46 | |
| Francesca DeMartino | Becton Dickinson and | N/A | |
| James Young | Abbott Laboratories | N/A | |
| Andrew Pierce | Stryker | 49 | |
| Scott Leinenweber | Abbott Laboratories | 51 | |
| Troy Kirkpatrick | Becton Dickinson and | N/A | |
| Elaine Leavenworth | Abbott Laboratories | 64 | |
| Jennifer Kirk | Medtronic PLC | 48 | |
| Mark Wilterding | Edwards Lifesciences | N/A | |
| JeanLuc Lemercier | Edwards Lifesciences | 66 | |
| Christine McCauley | Edwards Lifesciences | 58 | |
Management Performance
| Return On Equity | 0.0408 | |||
| Return On Asset | 0.0393 |
Boston Scientific Leadership Team
Elected by the shareholders, the Boston Scientific's board of directors comprises two types of representatives: Boston Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boston. The board's role is to monitor Boston Scientific's management team and ensure that shareholders' interests are well served. Boston Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boston Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jodi Eddy, VP Officer | ||
| Vance Brown, Gen VP | ||
| Catherine Jennings, VP Interventions | ||
| Joseph Fitzgerald, Ex Cardiology | ||
| John Sorenson, Ex Operations | ||
| Daniel Brennan, Ex CFO | ||
| Jeffrey Mirviss, Ex Interventions | ||
| Michael Mahoney, Pres Chairman | ||
| Jonathan Monson, Global VP | ||
| Susan Lisa, VP Relations |
Boston Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boston Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0408 | |||
| Return On Asset | 0.0393 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 72.27 B | |||
| Shares Outstanding | 1.43 B | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 94.00 % | |||
| Price To Earning | 317.20 X | |||
| Price To Book | 3.80 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Boston Stock
Boston Scientific financial ratios help investors to determine whether Boston Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Boston with respect to the benefits of owning Boston Scientific security.